PepGen Inc. (NASDAQ:PEPG – Get Free Report) insider Michelle L. Mellion sold 9,260 shares of PepGen stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $18.19, for a total value of $168,439.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Michelle L. Mellion also recently made the following trade(s):
- On Tuesday, June 11th, Michelle L. Mellion sold 500 shares of PepGen stock. The shares were sold at an average price of $18.04, for a total value of $9,020.00.
PepGen Stock Up 1.4 %
Shares of PEPG stock traded up $0.23 during mid-day trading on Wednesday, hitting $17.00. 115,500 shares of the stock were exchanged, compared to its average volume of 100,051. The firm has a fifty day moving average of $14.72 and a 200 day moving average of $12.33. The company has a market cap of $551.14 million, a PE ratio of -5.27 and a beta of 1.76. PepGen Inc. has a 52-week low of $3.72 and a 52-week high of $18.72.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on PEPG shares. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of PepGen in a report on Wednesday, May 15th. Wedbush reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of PepGen in a report on Wednesday, May 15th.
View Our Latest Stock Analysis on PEPG
Institutional Trading of PepGen
A number of institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC purchased a new position in PepGen in the 1st quarter valued at $30,000. Artal Group S.A. acquired a new stake in shares of PepGen in the first quarter valued at about $2,940,000. Adage Capital Partners GP L.L.C. raised its position in shares of PepGen by 18.3% in the third quarter. Adage Capital Partners GP L.L.C. now owns 680,000 shares of the company’s stock valued at $3,454,000 after buying an additional 105,000 shares during the last quarter. Vanguard Group Inc. raised its position in shares of PepGen by 68.0% in the first quarter. Vanguard Group Inc. now owns 850,445 shares of the company’s stock valued at $12,502,000 after buying an additional 344,266 shares during the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of PepGen by 18.1% in the first quarter. Janus Henderson Group PLC now owns 1,166,642 shares of the company’s stock valued at $17,225,000 after buying an additional 178,438 shares during the last quarter. 58.01% of the stock is owned by institutional investors and hedge funds.
PepGen Company Profile
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Featured Stories
- Five stocks we like better than PepGen
- 3 Warren Buffett Stocks to Buy Now
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Buy P&G Now, Before It Sets A New All-Time High
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- The Most Important Warren Buffett Stock for Investors: His Own
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.